CELMoDs are here, but are they here to stay?<br><br>CELMoD/IMiD review article: https://doi.org/10.1080/17474086.2024.2382897<br><br>Download the Oncology Learning Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

Iberdomide

OncoPharm

Welcome to OncoPharm. I'm your host, John Bossaer. I am a professor of pharmacy practice here at ETSU's Bill Gatt. This episode is sponsored by Kelly C. PharmD, an oncology education company for pharmacists. Today we have a new drug class to talk about. Cell mods. They are here. Are they here to stay? Let's discuss.

So last week the FDA approved ibertamide, or Zenbexis, which is a new oral agent for multiple myeloma. This is, I'm reading here from the PIA, a cereblon modulating protein degrader, or CELMOD, that's approved in combination with daratumumab hyaluronidase and dexamethasoneamethasone for myeloma patients

after at least one line of therapy, including a proteasome inhibitor and an IVID. What is, a couple notable things about this. First, this is the first drug approved for multiple myeloma based on, as an accelerated approval based on CR rate with minimum residual disease. FDA put out some guidance documents, you know, for comment a couple years ago saying, is this going to be a valid surrogate endpoint that society would value? And apparently it was.

And so this is the first drug approved based on MRD, complete response rate. This is known as a CELMOD, a cereblon modulating protein degrader. It's just an IMID, I think. And I'll talk about why. So when, you know, thalidomide and lilidomide were first used for multiple myeloma, we knew that they caused changes in cytokines.

You know, like your IL-2 levels would go up, I think, or TNF-alpha levels would go down. So it did some stuff to cytokine. It modulated the immune system. So they were known as IMIDs. And it wasn't until many years into the current IMID era that we learned the way these drugs actually work is they bind to cereblon, which is a protein...

Iberdomide

Read the full transcript

The candid version is on a podcast,
not the earnings call.

Iberdomide

Read the full transcript

The candid version is on a podcast, not the earnings call.

The candid version is on a podcast,
not the earnings call.